How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

637 results for

Renal Sympathetic Denervation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Synergy of pulmonary vein isolation and catheter renal denervation in atrial fibrillation complicated with uncontrolled hypertension: Mapping the renal sympathetic nerve and pulmonary vein (the pulmonary vein isolation plus renal denervation strategy)? (Abstract)

Synergy of pulmonary vein isolation and catheter renal denervation in atrial fibrillation complicated with uncontrolled hypertension: Mapping the renal sympathetic nerve and pulmonary vein (the pulmonary vein isolation plus renal denervation strategy)? Disturbance of sympathetic and vagal nervous system participates in the pathogenesis of hypertension and atrial fibrillation (AF). Renal denervation (RDN) can modulate autonomic nervous activity and reduce blood pressure (BP) in hypertensive

2019 Journal of cardiovascular electrophysiology Controlled trial quality: uncertain

2. Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation. (Abstract)

Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation. Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry.To assess the safety and efficacy of RDN on patients (...) , both P < 0.001; and 155 ± 17/89 ± 14 to 147 ± 18/82 ± 12 mmHg, both P < 0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up.In this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension

2018 Journal of Hypertension

3. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418) Overview | Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension | Guidance | NICE Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension Interventional procedures guidance [IPG418] Published date: January 2012 Share Save Guidance The National Institute (...) for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension. Description L43.6 Percutaneous transluminal radiofrequency denervation of renal artery Y53.- Approach to organ under image control L43.6 Percutaneous transluminal radiofrequency denervation of renal artery Y53.- Approach to organ under image control Your

2012 National Institute for Health and Clinical Excellence - Interventional Procedures

4. Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrill (Abstract)

Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrill Hypertension is an important, modifiable risk factor for the development of atrial fibrillation (AF). Even after pulmonary vein isolation (PVI), 20-40% experience recurrent AF. Animal studies have shown that renal denervation (RDN) reduces AF (...) group, 69 patients per group are required. We plan to randomize a total of 138 hypertensive patients with AF and signs of sympathetic overdrive in a 1:1 fashion. Patients should use at least two antihypertensive drugs. Sympathetic overdrive includes obesity, exercise-induced excessive blood pressure (BP) increase, significant white coat hypertension, hospital admission or fever induced AF, tachycardia induced AF and diabetes mellitus. The interventional group will undergo PVI + RDN and the control

2018 Clinical research in cardiology : official journal of the German Cardiac Society Controlled trial quality: uncertain

5. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. (Abstract)

Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. Atrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD (...) could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD.This was a single-center, prospective, longitudinal, randomized, double-blind study. The individuals were randomly divided into two groups (PVI + spironolactone, n = 36, and PVI + RSD, n = 33

2018 Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing Controlled trial quality: uncertain

6. Reduction of Blood Pressure Following After Renal Artery Adventitia Stripping During Total Nephroureterectomy: Potential Effect of Renal Sympathetic Denervation Full Text available with Trip Pro

Reduction of Blood Pressure Following After Renal Artery Adventitia Stripping During Total Nephroureterectomy: Potential Effect of Renal Sympathetic Denervation BACKGROUND Catheter-based renal sympathetic denervation has been reported to be effective for treatment resistance hypertension in Australia and Europe. However, in the blinded SYMPLICITY HTN-3 trial, renal denervation did not achieve a significant decrease in blood pressure (BP) in comparison to sham controls. There have been various (...) of catheter-based renal sympathetic denervation, although anesthesia, fluid infusion, and/or mesenteric traction may have had an influence. CONCLUSIONS A similar strategy involving thoracolumbar sympathectomy was reported about 50 years ago. The clinically significant blood pressure reduction in these patients suggests renal denervation is effective.

2018 The American journal of case reports

7. Renal sympathetic nerve activity after catheter-based renal denervation Full Text available with Trip Pro

Renal sympathetic nerve activity after catheter-based renal denervation Catheter-based renal sympathetic denervation (RDN) has been considered a potential treatment for therapy resistant hypertension (RHT). However, in a randomized placebo-controlled trial, RDN did not lead to a substantial blood pressure (BP) reduction. We hypothesized that variation in the reported RDN efficacy might be explained by incomplete nerve disruption as assessed by renal 123I-meta-iodobenzylguanidine (123I-mIBG (...) ). In addition, there was no significant correlation between the number of denervations and the renal 123I-mIBG parameters.No changes were observed in renal 123I-mIBG uptake or washout at 6 weeks post-RDN. These observations support incomplete renal denervation as a possible explanation for the lack of RDN efficacy.

2018 EJNMMI research Controlled trial quality: uncertain

8. Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. (Abstract)

Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial (...) variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored

2019 Journal of the American College of Cardiology

9. Number of ablated spots in the course of renal sympathetic denervation in CKD patients with uncontrolled hypertension: EnligHTN vs. Standard irrigated cardiac ablation catheter. (Abstract)

Number of ablated spots in the course of renal sympathetic denervation in CKD patients with uncontrolled hypertension: EnligHTN vs. Standard irrigated cardiac ablation catheter. Hypertension was both a mutual cause and the main concern of chronic kidney disease (CKD). Blood pressure control is more problematic in the company of CKD. This study compares the effects of renal sympathetic denervation (RSD) on 24-h ambulatory blood pressure measurements (ABPM) and renal function in individuals (...) . +21.4±8.7mL/min/1.73m2 (P=0.0222).The RSD reduced the mean 24-h ABPM in subjects with CKD and uncontrolled hypertension and improved the renal function in both groups. These effects were more marked and important in subgroups underwent a great number of ablated spots using the SICAC.Copyright © 2017 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.

2019 Hipertension y riesgo vascular Controlled trial quality: uncertain

10. Renal sympathetic denervation for treatment of hypertension: where are we now in 2019? (Abstract)

Renal sympathetic denervation for treatment of hypertension: where are we now in 2019? Although sound physiological principles and surgical precedent underpin renal denervation as a therapy for treatment resistant hypertension, and early clinical studies had produced encouraging results, the first sham-controlled study (SYMPLICITY HTN-3) failed to achieve its primary efficacy endpoint. Lessons learnt from this trial, and the knowledge derived from further animal and autopsy work, have been (...) applied in three recently published sham-controlled trials.These trials - SPYRAL OFF-MED, RADIANCE SOLO and SPYRAL ON-MED - using newer technologies, demonstrate a 5-10 mmHg incremental reduction in ambulatory SBP from RDN against sham-control, in patients with mild-to-moderate hypertension taking 0-3 drugs.These results provide proof of principle of the blood pressure-lowering effect of renal denervation. We now require data on long-term safety and durability of the procedure. Research is needed

2019 Current Opinion in Nephrology and Hypertension

11. Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension

Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension Ablación por radiofrecuencia de la inervación simpática de arterias renales para hipertensión arterial refractaria [Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension] Ablación por radiofrecuencia de la inervación simpática de arterias renales para hipertensión arterial refractaria [Actualization: radiofrequency (...) sympathetic denervation of the renal arteries for refractory arterial hypertension] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Dehese J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L

2014 Health Technology Assessment (HTA) Database.

12. Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney. Full Text available with Trip Pro

Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney. Sustained sympathetic activation contributes to the progression of myocardial cell injury, cardiac fibrosis, and left ventricular (LV) dysfunction in heart failure (HF).This study investigated the effects of radiofrequency renal nerve denervation (RF-RDN) on the pathobiology of HF and the interaction between the renal sympathetic nerves and natriuretic peptide (NP (...) with the beta1 antagonist bisoprolol inhibited renal neprilysin activity and increased circulation NP levels in WKY with HF.This study identifies a novel endogenous pathway by which the renal nerves participate in the degradation of cardioprotective NP. Furthermore, removal of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, augments circulating NP levels, reduces myocardial fibrosis, and improves LV function in the setting of HF.Copyright © 2017 American College

2017 Journal of the American College of Cardiology

13. Effect of renal sympathetic denervation on ventricular and neural remodeling. Full Text available with Trip Pro

Effect of renal sympathetic denervation on ventricular and neural remodeling. This study assessed the therapeutic effects of renal sympathetic denervation (RDN) on post-myocardial infarction (MI) ventricular remodeling and sympathetic neural remodeling in dogs. The possible mechanisms and optimal time for treatment are discussed.We randomly assigned 30 dogs to five groups: RDN 1 week before MI (RDN1w + MI; n = 6), RDN 1 week after MI (MI1w + RDN; n = 6), RDN 2 weeks after MI (MI2w + RDN; n = 6 (...) and of tyrosine hydroxylase (TH) in renal arteries was assessed by immunohistochemistry. Sympathetic innervations in the infarction border zone were investigated via Western blotting and real-time PCR.Left ventricular function in the MI group decreased significantly, while plasma BNP and ET-1 levels as well as MMP-2 and MMP-9 expression increased. Compared with the MI group, the RD groups showed significantly reduced MMP‑2, MMP‑9, TH, and growth-associated protein (GAP) 43 expression in the RDN1w + MI, MI1w 

2018 Herz Controlled trial quality: uncertain

14. Prevalence and consequences of noncardiac incidental findings on preprocedural imaging in the workup for transcatheter aortic valve implantation, renal sympathetic denervation, or MitraClip implantation. Full Text available with Trip Pro

Prevalence and consequences of noncardiac incidental findings on preprocedural imaging in the workup for transcatheter aortic valve implantation, renal sympathetic denervation, or MitraClip implantation. Dedicated data on the prevalence of incidental findings (IF) stratified according to overall clinical relevance and their subsequent correlation to outcome are lacking. The aim of the present study was to describe the prevalence and consequences of noncardiac IF on computed tomography (...) or magnetic resonance imaging in the workup for interventional cardiovascular procedures.A total of 916 patients underwent preprocedural computed tomography or magnetic resonance imaging in the workup for transcatheter aortic valve implantation (TAVI), renal sympathetic denervation (RDN), or MitraClip implantation.IF were found in 395 of 916 patients (43.1%), with an average of 1.8 IF per patient. Classifying the IF resulted in 155 patients with minor, 171 patients with moderate, and 69 patients

2018 American Heart Journal

15. Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation. (Abstract)

Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation. Renal sympathetic denervation (RDN) as treatment for hypertension shows highly variable results. Although some patients do not show any blood pressure (BP) change and in most patients a BP reduction of at least 5 mmHg can be found, some show a reduction at least 20 mmHg. We sought to identify predictors for such a profound BP response.Profound BP response was defined as drop of at least 20 mmHg (...) in daytime systolic ambulatory BP measurement (ABPM) 3 months after catheter-based RDN. Three different denervation devices were used for RDN, and pulse wave velocity was determined invasively in a subgroup of patients.One hundred and ninety consecutive patients were included in this analysis. Profound BP response was found in 33 patients. Patients with profound BP response were younger (P = 0.04), presented with higher baseline ABPM values (P < 0.001), were treated with ultrasound-based RDN and received

2018 Journal of Hypertension

16. Effects of renal sympathetic denervation on myocardial structure, function and perfusion: A serial CMR study. (Abstract)

Effects of renal sympathetic denervation on myocardial structure, function and perfusion: A serial CMR study. Echocardiographic studies have shown improvements in cardiac indices associated with renal sympathetic denervation (RDN), however, the benefits on myocardial perfusion have never been assessed. This trial was designed to study the effects of RDN on myocardial perfusion using cardiac magnetic resonance (CMR) imaging.A total of 14 patients with resistant hypertension were recruited (...) 46 ± 4% at baseline to 41 ± 8% at 6 months (p = 0.002).This study demonstrates that renal sympathetic denervation increased myocardial perfusion by 32% as assessed by CMR, and, this was associated with improvements in cardiac volumes and function. Larger well controlled and randomized studies are required to assess the clinical significance of these findings.Crown Copyright © 2018. Published by Elsevier B.V. All rights reserved.

2018 Atherosclerosis

17. Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)

Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03758196 Recruitment Status : Recruiting First Posted : November 29, 2018

2018 Clinical Trials

18. Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial Full Text available with Trip Pro

Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial Renal sympathetic denervation (RDN) is under investigation as a treatment option in patients with resistant hypertension (RH). Determinants of arterial compliance may, however, help to predict the BP response to therapy. Aortic distensibility (AD) is a well-established parameter of aortic stiffness and can reliably be obtained by CMR. This analysis sought

2018 Clinical Research in Cardiology

19. Accurate Depth of Radiofrequency-Induced Lesions in Renal Sympathetic Denervation Based on a Fine Histological Sectioning Approach in a Porcine Model Full Text available with Trip Pro

Accurate Depth of Radiofrequency-Induced Lesions in Renal Sympathetic Denervation Based on a Fine Histological Sectioning Approach in a Porcine Model Ablation lesion depth caused by radiofrequency-based renal denervation (RDN) was limited to <4 mm in previous animal studies, suggesting that radiofrequency-RDN cannot ablate a substantial percentage of renal sympathetic nerves. We aimed to define the true lesion depth achieved with radiofrequency-RDN using a fine sectioning method (...) and to investigate biophysical parameters that could predict lesion depth.Radiofrequency was delivered to 87 sites in 14 renal arteries from 9 farm pigs at various ablation settings: 2, 4, 6, and 9 W for 60 seconds and 6 W for 120 seconds. Electric impedance and electrode temperature were recorded during ablation. At 7 days, 2470 histological sections were obtained from the treated arteries. Maximum lesion depth increased at 2 to 6 W, peaking at 6.53 (95% confidence interval, 4.27-8.78) mm under the 6 W/60 s

2018 Circulation. Cardiovascular interventions

20. [Renal sympathetic denervation as treatment of resistant hypertension]

[Renal sympathetic denervation as treatment of resistant hypertension] Denervación simpática renal mediante ablación endovascular por radiofrecuencia en el tratamiento de la hipertensión arterial resistente [Renal sympathetic denervation as treatment of resistant hypertension] Denervación simpática renal mediante ablación endovascular por radiofrecuencia en el tratamiento de la hipertensión arterial resistente [Renal sympathetic denervation as treatment of resistant hypertension] Atienza Merino (...) G, Maceira Rozas MC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Atienza Merino G, Maceira Rozas MC. Denervación simpática renal mediante ablación endovascular por radiofrecuencia en el tratamiento de la hipertensión arterial resistente. [Renal sympathetic denervation as treatment of resistant hypertension] Santiago de Compostela

2013 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>